Novel Retinoic Acid Derivative Induces Differentiation and Growth Arrest in Neuroblastoma

Introduction: Retinoic acid (RA) is a differentiating agent utilized as maintenance therapy for high-risk neuroblastoma (NB), but associated toxicities and disease relapse limits its use. A novel rexinoid, 9-cis-UAB30 (UAB30), has been developed with a favorable toxicity profile compared to RA. We have previously shown that UAB30 decreased NB cell proliferation and in vivo tumor growth. A second generation, mono-methylated compound, 6-Methyl-UAB30 (6-Me), has been recently designed to have greater potency and negligible toxicity compared to UAB30. We …